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INTRODUCTION
Thyroid associated ophthalmopathy (TAO) is an autoimmune 
inflammatory orbital disorder most commonly associated with 
Graves’ disease (GD).1-4 According to Tanda, et al.,5 one-third of 
346 GD patients at a single center present ophthalmic manifes-
tation at their initial visit, and nearly 20% of patients who do 
not present Graves’ ophthalmopathy (GO) at their initial visit 
develop ophthalmopathy during the follow-up period. Al-
though the pathophysiology of this mechanism is not fully un-
derstood, the thyroid-stimulating hormone (TSH) receptor, 
which contains thyroid follicular cells and orbital connective 
tissue, might act as a common autoantigen.1,2,6 TSH receptor au-
toantibodies have been associated with the severity or activity of 
GO.7-9 Recently, several studies regarding the role of T helper 1- 
(CXCL 10) and T helper 2- (CCL2) chemokine in GO patho-
genesis were introduced.3,4
In terms of the association between TAO, GD, and thyroid 
cancer, patients with GD have a higher incidence of papillary 
thyroid cancer (PTC) than those without GD, which may be 
due to the higher thyroid hormone activity in GD patients than 
in the normal population.10 However, the development of hy-
perthyroid GD in patients with thyroid cancer is rare.11,12 In 1997, 
Kasuga, et al.12 showed that out of 1680 partial thyroidectomies 
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performed from 1966 to 1993 to remove thyroid nodules, only 
four GD cases (0.24%) were reported. Given that TAO is closely 
associated with hyperthyroidism, the development of TAO in 
patients diagnosed with thyroid cancer is presumably rare.
In the present study, we investigated the clinical characteris-
tics of TAO in patients who underwent total thyroidectomy for 
non-GD cases (i.e., thyroid cancer or a benign mass).
MATERIALS AND METHODS
We retrospectively reviewed the medical records of TAO pa-
tients who visited the Ophthalmology Department at Sever-
ance Hospital between March 2008 and March 2012 as well as 
selected patients who had undergone total thyroidectomy for 
thyroid nodules or cancer before the development of ophthal-
mopathy. Patients who had previous abnormal thyroid func-
tion, a history of GD, or any signs or symptoms of TAO prior to 
the thyroid operation were excluded from this study.
Diagnosis of TAO was made by one ophthalmology clinician 
(JSY) based on the following criteria: eyelid retraction, propto-
sis, extraocular muscle involvement, motility restriction, com-
puted tomography findings, and/or eyelid swelling.
Age, sex, treatment after total thyroidectomy, duration be-
tween total thyroidectomy and radioiodine (RAI) therapy, and 
duration between the surgery and ocular symptoms were report-
ed. Thyroid cancer staging was assessed based on the 2002 Amer-
ican Joint Committee on Cancer tumor node metastasis criteria.
All laboratory data at the time of ophthalmopathy occurrence 
were reviewed. Levels of 3,5,3’-triiodothyronine (T3), thyrox-
ine (T4), free T4, TSH, thyroglobulin (Tg), anti-peroxidase anti-
bodies (antiTPO), and TSH receptor antibodies, including thy-
roid-binding inhibitory immunoglobulin (TBII) and thyroid-
stimulating immunoglobulin (TSI), were investigated.
RESULTS
Of the 206 patients diagnosed with TAO, seven (3.4%) met the 
inclusion criteria. The mean age of the subjects was 47.4±8.1 
years, and all were female. Six patients were diagnosed with 
PTC, and one was diagnosed with a benign thyroid mass. Of 
the six patients diagnosed with PTC, two presented with stage 
I cancer, and four presented with stage III cancer. These four 
patients underwent a thyroid scan uptake test, and all showed 
positive findings. RAI treatment was performed on these four 
patients using a dose of 30 mCi (Table 1).
The duration between total thyroidectomy and onset of TAO 
ranged from 3–120 months (median 48 months). The ophthal-
mic manifestations varied among cases, with active TAO [clini-
cal activity score (CAS)≥3] diagnosed in four patients (cases 1, 
2, 6, 7), proptosis recorded in five patients (cases 1, 2, 4, 5, 6), 
and extraocular muscle limitation identified in two patients 
(cases 6, 7). One patient (case 3) presented with unilateral up-
per eyelid retraction only (Table 1, Fig. 1).
Except for one patient who was in the euthyroid state and 
diagnosed with a benign thyroid mass, all other patients were 
in the hyperthyroid state under Synthroid treatment. Five of 
the six patients who underwent the TSH receptor autoanti-
body test showed positive findings. Laboratory and clinical 
manifestations were summarized in Table 2.
Case 1
A 51-year-old woman presented with left upper eyelid retrac-
tion and left eye proptosis (Fig. 1A). Twenty-seven months pri-
or to the first visit to the ophthalmology department, she un-
derwent total thyroidectomy for PTC stage III. RAI (30 mCi) 
was performed 2 months after the surgery, after which she be-
gan taking Synthroid oral pills until her visit to the ophthalmo-
logic department. At the time of the visit, TSH was suppressed 
(less than 0.025 mIU/L), and the free T4 level was slightly ele-
vated (1.9 ng/dL). TBII and TSI were 2.38 IU/L and 441.4 per-
centage of specimen-to-reference ratio (SRR%), respectively. 
PET scan revealed no recurrence of thyroid cancer, and Tg was 
within normal limits (10.9 IU/mL). The CAS for TAO was 3, and 
triamcinolone was injected for the treatment of upper eyelid 
retraction.
Case 2
A 49-year-old woman presented with right upper eyelid retrac-
tion and right eye proptosis (Fig. 1B). She underwent total thy-
roidectomy for stage III PTC, and RAI was performed 1 month 
postoperatively. Four months later, she visited the ophthalmo-
logic department with ocular symptoms. The CAS was 3, and a 
3-mm right eye proptosis was identified. She was taking 0.15 
mg Synthroid. At the time of her visit, TSH was suppressed (0.14 
mIU/L), and the free T4 level was slightly elevated (2.53 ng/dL). 
TBII and TSI were not measured. Mullerectomy was performed 
for the treatment of upper eyelid retraction.
Case 3
A 47-year-old woman presented with right upper eyelid retrac-
tion (Fig. 1C). She underwent total thyroidectomy for stage III 
PTC, and RAI was performed 1 month later. After 3 months of 
RAI, she visited the ophthalmologic department with newly 
developed right upper eyelid retraction yet without any other 
specific findings. The patient was taking 0.15 mg Synthroid, 
and her thyroid function test revealed hyperthyroid status (TSH 
0.12 mIU/L, free T4 2.03 ng/dL). TBII was elevated (1.79 IU/L).
Case 4
A 55-year-old woman presented with both upper eyelid retrac-
tion and proptosis (Fig. 1D). Three months prior to her visit, she 
underwent total thyroidectomy for stage III PTC. RAI was per-
formed 1 month later. TBII was elevated (4.82 IU/L). The pa-
tient was taking 0.075 mg Synthroid, and a thyroid function test 
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revealed hyperthyroid status (TSH 0.4 mIU/L, free T4 1.65 ng/
dL). Tg was within normal limits (116.1 IU/mL).
Case 5
A 58-year-old woman presented with a 4-mm right eye pro-
ptosis (Fig. 1E). Her medical history revealed that she had un-
dergone total thyroidectomy for PTC stage I yet did not receive 
RAI therapy. She was taking 0.1 mg Synthroid, and her thyroid 
function test revealed hyperthyroid status (TSH <0.025 mIU/L, 
free T4 1.76 ng/dL). TBII and TSI bioassays were both within 
normal limits (0.38 IU/L and 53.9 SRR%, respectively), and both 
Tg (16.3 IU/mL) and antiTPO (10.5 IU/mL) were within normal 
limits.
Case 6
A 39-year-old woman presented with both ocular pain and 
swelling. She had undergone total thyroidectomy for a benign 
thyroid mass 10 years before her visit. She was not taking Syn-
throid, and her thyroid function was normal (TSH 0.22 mIU/L, 
free T4 1.31 ng/dL). Ophthalmic examination showed that CAS 
was 7, indicating severe active TAO. Upper eyelid retraction 
and a 24-mm proptosis were present in both eyes (Fig. 1F), as 
was diplopia in primary gaze. TBII (over 40 IU/L) and TSI (676 
SRR%) were significantly elevated; however, Tg was within nor-
mal limits (47.2 IU/mL). She was given systemic corticosteroid 
treatment for active TAO.
Case 7
A 44-year-old woman presented with a 3-month history of pain-
less diplopia (Fig. 1G). She underwent near-total thyroidecto-
my for PTC stage I. Ocular motility revealed limitation of su-
praduction with right eye hypotropia. Upper eyelid retraction 
was present in both eyes, and the CAS was 3. Tg (330.1 IU/mL) 
and the antiTPO level (447.4 IU/mL) were both elevated. She 
was taking 0.1 mg Synthroid. TSH was suppressed (less than 
0.025 mIU/L), and the free T4 level was slightly elevated (1.67 
ng/dL). TBII and TSI were 4.82 IU/L and 716 SRR%, respec-
tively. She was treated with right inferior rectus muscle reces-
sion for right hypotropia.
DISCUSSION
We reported seven rare cases of patients who developed TAO 
after total thyroidectomy for thyroid cancer or a benign mass 
of the thyroid. Interestingly, most patients showed abnormali-
ties in thyroid function and/or TSH receptor autoantibody tests 
at the time of TAO onset. Menconi, et al.13 compared overall im-
provement of Graves’ orbitopathy between near-total thyroid-
ectomy and total thyroid ablation groups, reporting better out-
comes of orbitopathy in the total thyroidectomy group. Winsa, 
et al.14 compared TSH receptor autoantibody levels and eye in-
volvement between subtotal thyroidectomy and total thyroid-
ectomy and found that those characteristics benefitted from 
total rather than subtotal thyroidectomy. These reports sup-
port the hypothesis that minimizing the remnant thyroid tissue 
may be beneficial for eye involvement through the removal of 
shared antigens and autoreactive T-lymphocytes.
Although the mechanisms through which TAO developed in 
these patients were unclear, we suggest several possibilities. In 
cases of euthyroid status, TAO development may be related to 
the presence of thyroid tissue that remains after total thyroid-
ectomy (with or without RAI). RAI and even the thyroidectomy 
surgery itself may also contribute to ophthalmopathy.
We assumed that cases 1, 5, 6, and 7 might be euthyroid TAO 
cases following total thyroidectomy. Thyroid tissue may have 
remained even after total thyroidectomy had been performed. 
Yoon, et al.15 performed a study on five TAO patients with thy-
Table 1. Patients’ General Characteristics
No. Age Sex
Thyroid disease diagnosis, 
cancer stage
Radioactive 
iodine therapy
Duration between 
RAI and total 
thyroidectomy
Duration between 
surgery and ocular 
symptoms (months)
Ophthalmic 
manifestation
Ophthalmologic 
treatment
1 51 F Papillary cancer, III Done 2 27 
Left upper ELR
  3-mm left proptosis 
Triamcinolone
2 49 F Papillary cancer, III Done 1 4
Right upper ELR
  3-mm right proptosis
Mullerectomy
3 47 F Papillary cancer, III Done 2 4 Right upper ELR Triamcinolone
4 55 F Papillary cancer, III Done 4 3
Both upper ELR
Both eye proptosis
Triamcinolone
5 58 F Papillary cancer, I Not done 75 4-mm right proptosis No treatment
6 39 F Benign mass N/A 120
Both proptosis, 
  LOM diplopia CAS 7
PDL, 
  Solu-Medrol
7 44 F Papillary cancer, I Not done 48
Both upper ELR, 
  LOM, diplopia
PDL, Solu-Medrol,
  RIR recession
N/A, not applicable; ELR, eyelid retraction; LOM, limitation of motion; CAS, clinical activity score; PDL, prednisolone; RIR, right inferior rectus; RAI, radioiodine; 
CAS, clinical activity score.
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roid cancer who tested positive for TBII yet showed normal 
thyroid function, suggesting that TAO may develop due to sys-
temic autoimmunity and may not be induced by hyperthyroid-
ism. Case reports of euthyroid TAO several decades ago also 
describe patients with ocular signs of TAO and normal thyroid 
function without previous history of hyperthyroidism.16,17 To 
Fig. 1. (A) Case 1 shows left upper eyelid retraction. (B) Case 2 shows right upper eyelid retraction. (C) Case 3 shows right upper eyelid retraction. (D) Case 
4 shows both upper eyelid retraction and eyelid swelling. (E) Case 5 shows right eye proptosis. (F) Case 6 shows eyelid swelling and erythema, both con-
junctival injection and severe proptosis. (G) Case 7 shows right hypotropia.
A
C
E
G
B
D
F
Table 2. Patients’ Laboratory Characteristics
No. Age Sex Current thyroid treatment Tg level AntiTPO fT4 TSH TBII TSI 
1 51 F Synthroid 0.1 mg 10.9 NC 1.9 <0.025 2.38 441.1
2 49 F Synthroid 0.15 mg <5.5 NC 2.53 0.14 NC NC
3 47 F Synthroid 0.15 mg <5.5 NC 2.03 0.12 1.79 NC
4 55 F Synthroid 0.075 mg 116.1 NC 1.65 0.4 4.82 NC
5 58 F Synthroid 0.1 mg 16.3 10.5 1.76 <0.025 0.38 53.9
6 39 F N/A 47.2 NC 1.31 0.22 >40 676
7 44 F Synthroid 0.1 mg 330.1 447.4 1.67 <0.025 4.82 716
NC, not checked; N/A, not applicable; Tg, thyroid globulin; antiTPO, anti-thyroid peroxidase antibodies; TSH, thyroid stimulating hormone; TBII, thyroid-binding 
inhibitory immunoglobulin; TSI, thyroid-stimulating immunoglobulin; fT4, free thyroxine; SRR%, percentage of specimen-to-reference ratio.
Normal range: TBII 0–1.75 IU/L, TSI 0–140 SRR%, Tg Level 0–130.6 IU/mL, antiTPO 0–13.7 IU/mL, TSH 0.4–3 mIU/L, free T4 0.7–1.48 ng/dL.
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our knowledge, our study is the first to report euthyroid TAO 
following total thyroidectomy. In the present study, case 6 
demonstrated severe active TAO despite undergoing total thy-
roidectomy for a benign thyroid mass 10 years prior to the 
ophthalmology department visit. Thyroid function and Tg 
were all within normal limits at the time of TAO development; 
however, TBII and TSI titer were considerably elevated. As it 
was a benign mass, the patient did not receive RAI, which may 
have removed the remaining thyroid tissue. Therefore, we hy-
pothesized that the remaining thyroid tissue may have induced 
abnormal thyroid autoimmunity even without any change in 
thyroid hormone. Following total thyroid ablation, a subse-
quent elevation of the serum Tg level is an indication of recur-
rence or metastasis of thyroid cancer. However, in case 7, the 
patient underwent near-total thyroidectomy for PTC stage I, 
and RAI was not performed. In this patient, the elevated Tg 
(330.1 IU/mL) level meant that there was certainly remaining 
thyroid tissue.
Of the six patients with PTC in the present study, four had 
stage III cancer. After total thyroidectomy and RAI, thyroid 
hormone was administered routinely to correct hypothyroid-
ism and suppress serum TSH to less than 0.1 μU/mL, which 
inhibited the growth of remaining TSH-dependent thyroid 
cancer cells. In most of our cases, administrating thyroid hor-
mone suppressed TSH and increased free T4. Although hyper-
thyroid status may not influence ophthalmopathy directly, it 
may have secondary effects on TAO through its negative influ-
ence of thyroid autoimmunity.
In three patients (cases 2, 3, and 4), TAO onset was closely re-
lated to RAI treatment after thyroidectomy. The relationship 
between RAI treatment and worsening of ophthalmopathy is 
well-documented.18,19 Radiation injury may result in the release 
of the TSH receptor, which is a common antigen involved in GD 
and ophthalmopathy. Two unusual TAO cases have been re-
ported recently. One involved a patient with metastatic thyroid 
cancer who developed TAO after RAI and external beam radia-
tion.20 The other case involved a patient with disseminated thy-
roid cancer and no previous autoimmune thyroid disease who 
developed TAO after RAI treatment while under recombinant 
human thyrotropin and retinoic acid treatments, indicating that 
radiation-associated thyroid injury may contribute to TAO in 
patients with thyroid cancer.21
Considering that ophthalmopathy occurred 3–4 months af-
ter thyroidectomy in several of our cases, ophthalmopathy may 
be related to the thyroidectomy itself. Several previous cases 
have shown the development of GD shortly after thyroid can-
cer surgery.11,12 Although the mechanism for GD development 
after partial thyroidectomy is unclear, several hypotheses have 
been suggested. The first hypothesis is that the operation de-
stroys thyroid cells, which may increase TSH receptor expres-
sion and thereby lead to GD.12 A second hypothesis is that the 
operation causes postoperative GD by inducing an immune 
system abnormality, such as the stimulation of the antigen-pre-
senting cells that control the activation of suppressor or regula-
tory cells. A third hypothesis is that the stress from general an-
esthesia and surgery affects the patients physically and 
mentally, thereby causing neuroendocrine fluctuations that 
disrupt immunological homeostasis. One final hypothesis is 
that postoperative bacterial and viral infections increase the 
number of CD5+ B cells, which stimulate the TSH receptor an-
tibodies and thus contribute to GD.11
In conclusion, ophthalmopathy rarely develops in patients 
after total thyroidectomy for thyroid diseases other than GD, 
and the pathogenesis of TAO in these other thyroid diseases is 
unclear. However, thyroid hormonal function and TSH recep-
tor antibody tests, which were conducted in most patients that 
showed ophthalmic symptoms, yielded abnormal results. Our 
results, combined with previous literature, indicated several 
possibilities for the pathogenesis of TAO. First, euthyroid TAO 
may be caused by thyroid tissues that remain after total thy-
roidectomy (with or without RAI). Second, RAI may contribute 
to the development of ophthalmopathy. Third, the surgery it-
self may lead to ophthalmopathy.
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